Stroke Treatment: Thrombolytics, Thrombectomy, and Acute Intervention

Acute stroke treatment is a time-critical medical emergency in which the choice of intervention—clot-dissolving medication, mechanical clot removal, or both—depends on stroke type, elapsed time, and patient-specific anatomy. This page covers the two primary acute treatment pathways for ischemic stroke, the contraindications that define their use, and the clinical decision framework that governs when each applies. Understanding these distinctions matters because the window for effective intervention is measured in minutes, and inappropriate treatment of hemorrhagic stroke with thrombolytics carries life-threatening risk.

Definition and scope

Stroke treatment at the acute phase addresses the pathological interruption of cerebral blood flow. The American Heart Association / American Stroke Association (AHA/ASA) publishes guidelines that form the clinical backbone for acute stroke management across US hospital systems, with the most recent comprehensive revision released in 2019 (AHA/ASA Stroke Guidelines, Stroke journal, 2019).

Two interventions dominate the acute ischemic stroke landscape:

These interventions apply only to ischemic stroke, which accounts for approximately 87 percent of all strokes according to the Centers for Disease Control and Prevention (CDC). Hemorrhagic stroke—caused by vessel rupture rather than occlusion—requires entirely different management, and thrombolytics are absolutely contraindicated in that context.

The /regulatory-context-for-neurological framework governing stroke care spans FDA drug approval status, The Joint Commission's Comprehensive Stroke Center certification standards, and CMS quality metrics tied to hospital reimbursement under the Inpatient Prospective Payment System.

How it works

Intravenous Thrombolysis (IV-tPA)

Alteplase binds to fibrin within a thrombus and converts plasminogen to plasmin, which degrades the clot matrix. The FDA-approved dosing for alteplase in acute ischemic stroke is 0.9 mg/kg (maximum 90 mg total), with 10 percent delivered as an IV bolus and the remainder infused over 60 minutes (FDA label for Activase/alteplase).

Tenecteplase (TNK-tPA) has a simpler single-bolus delivery and is increasingly used in systems that have adopted it under evolving AHA/ASA guidance, though alteplase remains the longer-established standard.

The critical performance metric is door-to-needle (DTN) time: AHA/ASA guidelines set a benchmark of 60 minutes or less from hospital arrival to drug administration, with a target of 45 minutes considered achievable in high-performing centers.

Mechanical Thrombectomy

Thrombectomy involves:

  1. Arterial access: Typically via the femoral artery, with radial access used in select anatomies.
  2. Catheter navigation: A microcatheter is advanced through the aorta and into the intracranial circulation under fluoroscopic guidance.
  3. Clot engagement: A stent retriever is deployed across the thrombus, or a large-bore aspiration catheter is positioned at the clot face.
  4. Retrieval: The stent retriever is withdrawn with the thrombus captured, or suction is applied to extract the clot.
  5. Reperfusion confirmation: Post-procedure angiography confirms vessel patency using the modified Thrombolysis in Cerebral Infarction (mTICI) scale; mTICI 2b/3 is the standard target for successful reperfusion.

The performance benchmark for thrombectomy is door-to-groin puncture time of 90 minutes or less and door-to-reperfusion of 120 minutes or less, per AHA/ASA recommendations. The Joint Commission's Comprehensive Stroke Center certification program uses these metrics to evaluate hospital-level performance.

Common scenarios

Three clinical presentations illustrate how the two interventions are applied:

Scenario 1 — IV-tPA eligible, no large vessel occlusion (LVO)
A patient arrives within 3 hours of symptom onset with moderate deficit, no hemorrhage on CT, and no imaging evidence of proximal vessel occlusion. IV-tPA is initiated. No thrombectomy is indicated because there is no large clot amenable to mechanical retrieval.

Scenario 2 — Combined IV-tPA and thrombectomy (bridging therapy)
A patient presents within 4.5 hours with severe deficits and CT angiography confirms middle cerebral artery (MCA) M1 segment occlusion. IV-tPA is administered first while the endovascular team is mobilized. Thrombectomy follows. This "bridging" approach remains standard in most US comprehensive stroke centers.

Scenario 3 — Thrombectomy alone, extended window
A patient awakens with deficits of unknown onset but MRI diffusion-perfusion mismatch (or CT perfusion) demonstrates viable penumbra. The patient is outside the 4.5-hour tPA window but within 24 hours of last known well. Based on data from the DAWN and DEFUSE 3 trials (published 2018), thrombectomy may be performed without prior tPA. These trials established that perfusion imaging can identify salvageable tissue well beyond the traditional time cutoffs.

For a clinical overview of stroke types and warning signs, including the differentiation between ischemic and hemorrhagic presentations, the linked page provides structural context.

Decision boundaries

The following numbered framework captures the primary branch points governing treatment eligibility:

  1. Confirm stroke type: Non-contrast CT of the head rules out hemorrhage. Thrombolytics are never given if hemorrhage is present.
  2. Establish time of symptom onset or last known well: IV-tPA window is 3 hours for standard eligibility; extended to 4.5 hours for patients meeting specific criteria (AHA/ASA 2019, Class I recommendation). Thrombectomy window extends to 24 hours in perfusion-selected patients.
  3. Evaluate LVO status: CT angiography identifies proximal occlusions (internal carotid artery, MCA M1/M2, basilar artery) that are mechanically retrievable. Distal or small-vessel occlusions are not candidates for thrombectomy.
  4. Screen absolute contraindications to tPA: These include active intracranial hemorrhage, recent intracranial or spinal surgery within 3 months, platelet count below 100,000/µL, and current anticoagulation with INR above 1.7, among others defined in AHA/ASA guidelines.
  5. Assess core infarct volume: Large established infarct on CT or MRI (greater than 70–100 mL in core by perfusion imaging) reduces the benefit of reperfusion and increases hemorrhagic transformation risk.
  6. Determine destination facility: Primary Stroke Centers can deliver IV-tPA; Thrombectomy-Capable Stroke Centers and Comprehensive Stroke Centers have the endovascular infrastructure for MT. The Joint Commission and DNV GL Healthcare certify these facility tiers.

The distinction between primary and comprehensive stroke centers is not merely administrative. CMS links stroke quality measures, including tPA administration rates and 30-day mortality, to hospital value-based purchasing calculations under 42 CFR Part 412.

Long-term recovery pathways following acute intervention are addressed in depth at rehabilitation after neurological injury, and an overview of the full neurological care landscape is available at the site index.

References

The law belongs to the people. Georgia v. Public.Resource.Org, 590 U.S. (2020)